Vaccines Respiratory
COVID Vaccine Sales, 2023 to 2025
Pfizer-booked Comirnaty and Moderna COVID product sales. The APA world became a seasonal market in two years.
Adult RSV Vaccine Sales, 2023 to 2025
Arexvy vs Abrysvo vs mRESVIA. ACIP made adult RSV a single dose, not an annual franchise. GBP converted at that year's IRS average.
Infant RSV Prevention: Beyfortus Sales
The disclosed infant RSV P&L is a monoclonal antibody, not a vaccine. Maternal Abrysvo is not split out; Merck Enflonsia launched June 2025 without a franchise line.
Flu Franchise Sales, 2025
Sanofi flu/COVID bundle, Seqirus Fluad and Flucelvax (FY June 2025), GSK influenza, and Moderna mFLUSIVA at zero 2025 sales. Not like-for-like periods.
COVID plus Flu Combo Pipeline
Who can sell a single-injection respiratory franchise. RSV stays a separate ACIP product in 2026.
| Program | Company | Components | Status | Note |
|---|---|---|---|---|
| mCOMBRIAX (mRNA-1083) | Moderna | COVID + flu | EU-approved; US path follows mFLUSIVA | Single-injection respiratory franchise. US timing depends on flu label plus combination data. |
| mFLUSIVA (mRNA-1010) | Moderna | Flu only | FDA 5 Aug 2026, adults 50+ | First US mRNA flu shot. Traditional approval 50-64; accelerated 65+. ACIP still the demand switch. |
| Pfizer/BioNTech flu + COVID | Pfizer / BioNTech | COVID + flu | In development | Defends the Comirnaty seasonal slot with one injection. |
| Sanofi + Novavax Nuvaxovid | Sanofi / Novavax | COVID protein; flu separate | Nuvaxovid in selected Sanofi markets | Not a single-shot combo. Sanofi leads selected-market COVID commercial. |
| Arexvy / Abrysvo / mRESVIA | GSK / Pfizer / Moderna | RSV only | Approved; not annual | No commercial COVID+flu+RSV triple in 2026. RSV remains a separate visit. |
ACIP RSV Recommendation Path
Arexvy sales were £1,238m in 2023, £590m in 2024 and £593m in 2025 (GSK). Shared clinical decision-making in 2023, then single-dose 75+ in 2024.
FDA approves Arexvy (3 May 2023) and adult Abrysvo (31 May 2023)
The first two US RSV vaccines, both for adults 60 and older.
ACIP: shared clinical decision-making on a single dose for adults 60+ (21 Jun 2023)
First recommendation is optional, not routine.
FDA approves maternal Abrysvo (21 Aug 2023)
Opens a pregnancy indication that protects infants from birth through 6 months. A different group from Arexvy's older-adult slot.
FDA approves mRESVIA (31 May 2024)
Third US RSV vaccine. Share fight, not a new TAM.
ACIP: single dose for all adults 75+ and for adults 60-74 at increased risk
The load-bearing vote. Single dose, age-gated. Arexvy sales fell from £1,238m (2023) to £590m (2024); GSK cites a more limited ACIP recommendation and channel inventory consumption after launch-year stocking.
ACIP adds 50-59 at increased risk (vote 16 Apr 2025)
Widens eligibility; still a single dose. Not confirmed in a primary source as of 2026-10-31: CDC adoption on 25 Jun 2025.
FDA approves Enflonsia (clesrovimab) on 9 Jun 2025
Second infant mAb. Infant prevention is now antibodies (Beyfortus, Enflonsia) plus maternal Abrysvo.
US Adult Respiratory Coverage, 2025-26 Season
CDC NIS-FRVM as of 22 Feb 2026. Flu and COVID are this-season coverage. RSV is ever received a dose.